TruScreen censured, fined for director shortage
The NZ Markets Disciplinary Tribunal says companies need succession planning for directors.
Dane Ambler
Tue, 13 Feb 2018
Cervical cancer test developer TruScreen has been censured by the NZ Markets Disciplinary Tribunal for only having one New Zealand resident director for 18 business days.
The tribunal said TruScreen had only one director who was a New Zealand resident following its annual meeting on September
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Subscribe Now
Monthly Premium Online Subscription
NZ$49.95 / monthly
Subscribe Now
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Subscribe Now
Yearly Premium Online Subscription
NZ$499.00 / yearly
Subscribe Now
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Subscribe Now
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Subscribe Now
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Dane Ambler
Tue, 13 Feb 2018
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.